There are significant barriers to the successful implementation of Precision Medicine technologies both in Canada and internationally. Many of these barriers are related to the ethical, environmental, economic, legal and social aspects of Genomics research (GE3LS). In 2013 Genome Canada funded 17 Genomics and Personalized Health (GAPH) Large Scale Applied Research Projects focused on bringing genomics technologies to market. By 2015 it had become clear that GE3LS knowledge was siloed within individual projects. Genome Canada recognized that substantial value could be obtained by establishing a collaborative network for sharing and synthesizing the GE3LS knowledge and experience that had developed within the research teams.
On March 17th, 2016, the Canadian Government, via Genome Canada, announced the funding of the Precision Medicine Policy Network, a collaborative ‘learning network’ of the 17 GAPH Projects (press announcement: EN; FR).
The Government of Canada is pleased to support this exceptional Network, which is paving the way for personalized medicine to be integrated more fully into the health care system for the benefit of Canadians.
The Honourable Kirsty Duncan, Minister of Science
We are proud to support this new Network that will encourage synergies and sharing of expertise, methods and tools that will lead to improved outcomes and impacts on the health of Canadians.
Mr. Marc LePage, President and CEO, Genome Canada
The Precision Medicine Policy Network brings together top researchers from across Canada to address four high priority themes:
- Theme 1: Research ethics review
- Theme 2: Health economics and health technology assessment
- Theme 3: Knowledge transfer and implementation in health systems
- Theme 4: Intellectual property and commercialization
Network outputs will accelerate the translation of Genomics research and technologies into practical healthcare applications, for the benefit of patients.
NEWS from the Network: March 2017, Issue 3